Zevra Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders, electing directors, ratifying the appointment of Ernst & Young LLP as the independent registered public accounting firm, approving executive officer compensation, and not approving amendments to the equity incentive plan.